WHO Pharmaceutical Prequalification Intelligence Dashboard (2002–2026): 572 Products, 17 Therapeutic Areas

By abhishek.verma75000 · May 3, 2026

Analysis of 572 WHO prequalified pharmaceutical products (2002–2026) highlighting trends across therapeutic areas, applicants, dosage forms, and drug…

A horizontal bar chart has been generated showing the top 10 most common dosage forms among prequalified products. The chart ranks each dosage form by the number of products, with color intensity indicating relative frequency. You can explore the full breakdown in the accompanying data table.

The number of prequalifications has grown significantly since 2002, reaching a peak of 52 in 2020. A line chart has been generated showing the full yearly trend from 2002 to 2026, along with a data table of the counts per year.

The breakdown of products by Basis of Listing has been analyzed and visualized. Two charts were generated — a bar chart showing the count of products for each listing basis, and a pie chart illustrating the proportional distribution across all categories.

The bar chart and table show the top 10 applicants with the most prequalified pharmaceutical products. Macleods Pharmaceuticals Ltd dominates the list with 90 products, nearly double the second-place Mylan Laboratories Ltd, which has 50 products. The top 10 are all major generic pharmaceutical manufacturers, primarily from India.

The 669 prequalified products are spread across 17 therapeutic areas. HIV/AIDS dominates the portfolio with 263 products (39.31%), followed by Tuberculosis with 130 products (19.43%) and Malaria with 101 products (15.1%). Together, these top three areas account for nearly 74% of all prequalified products. A bar chart and pie chart have been generated to visually illustrate this distribution.

The analysis reveals how product types are distributed across 16 therapeutic areas, with only 2 distinct product types in the dataset. Two visualizations were generated: a stacked bar chart and a heatmap showing product type counts across the top 10 therapeutic areas.

Out of 669 total products, 96 (14.3%) have a non-null 'Basis of alternative listing', while the remaining 573 products (85.7%) do not have this field populated. Two visualizations were generated: a pie chart showing the distribution of the top alternative listing bases, and a bar chart breaking down all unique values within the 96 alternatively listed products.

The horizontal bar chart shows the top 15 applicants ranked by their therapeutic area breadth — the number of distinct therapeutic areas they cover. Mylan Laboratories Ltd. tops the ranking with the widest portfolio breadth of 7 therapeutic areas and 50 total products. The grouped bar chart lets you visually compare each applicant's diversity (breadth score in blue) against their volume (total products in orange), making it easy to spot whether an applicant's strength comes from diversity, sheer volume, or both.

The analysis successfully processed the prequalification dataset and produced data tables showing yearly product counts broken down by Therapeutic Area. Three data tables were generated capturing the yearly-by-therapeutic-area breakdown, yearly totals, and the top 3 most active years for prequalification activity.

The analysis parsed the 'INN, Dosage Form and Strength' column to extract active ingredient names and identify the most frequently appearing drug substances in the dataset. Two data tables were generated showing the top 15 active ingredients along with their counts, percentages, and primary therapeutic areas.